FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	.C. 20549
---------------	-----------

Check this box if no longer subject to	S
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number: 3235-0287									
	Estimated average burden									
1	hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LAPPE RODNEY W</u>				2. Issuer Name and Ticker or Trading Symbol Design Therapeutics, Inc. [DSGN]								telationship eck all appl X Direct	icable)	g Pers	son(s) to Iss			
(Last)	(Fi	rst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/31/2023								Office below	r (give title)		Other (s below)	pecify
C/O DESIGN THERAPEUTICS, INC. 6005 HIDDEN VALLEY ROAD, SUITE 110				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street)	BAD C	A	92011											Form Perso		e thar	n One Repor	ting
(City)	(Si	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								d to					
Table I - Non-Derivativ 1. Title of Security (Instr. 3) 2. Transactio						ative Securities Acquired, Disposed of, or Benefici								ly Owne		6. Ownership		7. Nature
Date (Month/Da					ay/Year) if a		Execution Date, if any (Month/Day/Year		on str.		ed Of (D) (Instr. 3, 4		Securit Benefic Owned	Securities Beneficially Owned Following	Form: Direct (D) or Indirect (I) (Instr. 4)	n: Direct r Indirect istr. 4)	of Indirect Beneficial Ownership	
								Code	v	Amount	(A) o (D)	r Price		ansaction(s) str. 3 and 4)			(Instr. 4)	
		Т							uired, Dis , options	•	,		•	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transact Code (In 8)		of		6. Date Exer Expiration E (Month/Day/	ate	Amount of		f g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$5.63	05/31/2023			A		15,000		(1)	05.	/30/2033	Common Stock	15,000	\$0.00	15,000)	D	

Explanation of Responses:

1. The shares subject to the option vest in equal monthly installments over 12 months following May 31, 2023 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.

Remarks:

/s/ Mustapha Parekh, Attorneyin-Fact

** Signature of Reporting Person

06/02/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.